La auténtica dimensión del colesterol-no-HDLcolesterol aterogénico
- Millán, Jesús
- Hernández-Mijares, Antonio
- Ascaso, Juan F.
- Blasco, Mariano
- Brea, Angel
- Díaz, Ángel
- González-Santos, Pedro
- Mantilla, Teresa
- Pedro-Botet, Juan
- Pintó, Xavier
ISSN: 0214-9168, 1578-1879
Any de publicació: 2016
Volum: 28
Número: 6
Pàgines: 265-270
Tipus: Article
Altres publicacions en: Clínica e investigación en arteriosclerosis
Resum
Lowe density lipoproteins (LDL) are the causal agent of cardiovascular diseases. In practice, we identify LDL with cholesterol transported in LDL (cLDL). So, cLDL has become the major target for cardiovascular prevention. Howewer, we have progressive evidences about the role of triglycerides rich lipoproteins, particularly those very low density lipoprotein (VLDL) in promotion and progression of atherosclerosis, that leads cholesterol in VLDL and its remanents as a potential therapeutic target. This feature is particularly important and of a great magnitude, in patients with hypertiglyceridemia. We can to considere, that the non-HDL cholesterol –cLDL + cVLDL + c-remmants + Lp(a)– is the real measurement of atherogenic cholesterol. In addition, non-HDL-cholesterol do not show any variations between postprandial states. In fact, non-HDL-cholesterol should be an excellent marker of atherogenic cholesterol, and an major therapeutic target in patients with atherogenic dyslipidaemia. According with different clinical trials and with the epidemiological and mendelian studies, in patients with high cardiovascular risk, optimal level of cLDL will be under 70 mg/dl, and under 100 ng/dl for non-HDL-cholesterol; and in high risk patients, 100 mg/dl and 130 mg/dl, respectively.